Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
Predictive Value of C-reactive Protein for Hospitalization and Mortality Among People With Advanced HIV Disease in Uganda Receiving the World Health Organization-recommended Package of Care.
СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schwartz Elizabeth L, Nalintya Elizabeth K, Skipper Caleb P, Nerima Patricia, Fieberg Ann M, Namakula Olive L, Dai Biyue, Meya David B, Boulware David R, Rajasingham Radha
Аннотация
BACKGROUND: People with advanced human immunodeficiency virus (HIV) disease (CD4 ≤ 200 cells/µL) remain at high risk for opportunistic infections, hospitalization, and death, despite access to antiretroviral therapy (ART). We evaluated serum C-reactive protein (CRP) as a predictor of 30-day hospitalization or death among outpatients with advanced HIV disease.
METHODS: We prospectively enrolled 1388 outpatient Ugandan adults with CD4 ≤ 200 cells/µL from May 2022 to February 2025, of whom 1378 had serum CRP measured at enrollment. Participants were ART-naïve or experienced, and people with known virologic suppression were excluded. Participants received tuberculosis and cryptococcosis screening and therapy per World Health Organization (WHO) recommendations. We examined CRP as a continuous and dichotomized predictor (≥10 mg/L) of 30-day hospitalization or death.
RESULTS: Among 1378 participants, 41.6% had CRP ≥10 mg/L. Participants with CRP ≥10 mg/L were more likely to be hospitalized (relative risk = 4.2, 95% CI: 2.3-7.8) or die (relative risk = 9.8, 95% CI: 2.9-32.8) within 30 days. In a multivariable Cox model adjusted for weight, CD4 count, ART status, and age, each 2-fold increase in CRP was associated with a 36.9% higher hazard of 30-day hospitalization or death (hazard ratio = 1.4, 95% CI: 1.2-1.5). Including CRP in the multivariable model significantly improved prediction of 30-day hospitalization or death (AUC 0.80 with CRP vs 0.72 without, DeLong's P = .009).
CONCLUSIONS: CRP ≥10 mg/L is associated with increased risk of 30-day hospitalization or death among outpatients with advanced HIV disease receiving the WHO-recommended package of care. Prospective studies should evaluate whether point-of-care CRP testing can enable real-time risk stratification to reduce AIDS-related deaths.
METHODS: We prospectively enrolled 1388 outpatient Ugandan adults with CD4 ≤ 200 cells/µL from May 2022 to February 2025, of whom 1378 had serum CRP measured at enrollment. Participants were ART-naïve or experienced, and people with known virologic suppression were excluded. Participants received tuberculosis and cryptococcosis screening and therapy per World Health Organization (WHO) recommendations. We examined CRP as a continuous and dichotomized predictor (≥10 mg/L) of 30-day hospitalization or death.
RESULTS: Among 1378 participants, 41.6% had CRP ≥10 mg/L. Participants with CRP ≥10 mg/L were more likely to be hospitalized (relative risk = 4.2, 95% CI: 2.3-7.8) or die (relative risk = 9.8, 95% CI: 2.9-32.8) within 30 days. In a multivariable Cox model adjusted for weight, CD4 count, ART status, and age, each 2-fold increase in CRP was associated with a 36.9% higher hazard of 30-day hospitalization or death (hazard ratio = 1.4, 95% CI: 1.2-1.5). Including CRP in the multivariable model significantly improved prediction of 30-day hospitalization or death (AUC 0.80 with CRP vs 0.72 without, DeLong's P = .009).
CONCLUSIONS: CRP ≥10 mg/L is associated with increased risk of 30-day hospitalization or death among outpatients with advanced HIV disease receiving the WHO-recommended package of care. Prospective studies should evaluate whether point-of-care CRP testing can enable real-time risk stratification to reduce AIDS-related deaths.